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Toll-like receptor 7 deficiency suppresses type 1 diabetes
development by modulating B-cell differentiation and function
Juan Huang1,2, Jian Peng2, James Alexander Pearson 2,3, Georgios Efthimiou2,4, Youjia Hu2, Ningwen Tai2, Yanpeng Xing2,5,
Luyao Zhang2,5, Jianlei Gu6, Jianping Jiang6, Hongyu Zhao6, Zhiguang Zhou1, F. Susan Wong3 and Li Wen 2
Innate immunity mediated by Toll-like receptors (TLRs), which can recognize pathogen molecular patterns, plays a critical role in
type 1 diabetes development. TLR7 is a pattern recognition receptor that senses single-stranded RNAs from viruses and host tissue
cells; however, its role in type 1 diabetes development remains unclear. In our study, we discovered that Tlr7-deficient (Tlr7−/−)
nonobese diabetic (NOD) mice, a model of human type 1 diabetes, exhibited a significantly delayed onset and reduced incidence of
type 1 diabetes compared with Tlr7-sufficient (Tlr7+/+) NOD mice. Mechanistic investigations showed that Tlr7 deficiency
significantly altered B-cell differentiation and immunoglobulin production. Moreover, Tlr7−/− NOD B cells were found to suppress
diabetogenic CD4+ T-cell responses and protect immunodeficient NOD mice from developing diabetes induced by diabetogenic
T cells. In addition, we found that Tlr7 deficiency suppressed the antigen-presenting functions of B cells and inhibited cytotoxic
CD8+ T-cell activation by downregulating the expression of both nonclassical and classical MHC class I (MHC-I) molecules on B cells.
Our data suggest that TLR7 contributes to type 1 diabetes development by regulating B-cell functions and subsequent interactions
with T cells. Therefore, therapeutically targeting TLR7 may prove beneficial for disease protection.
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INTRODUCTION
Type 1 diabetes (T1D) is an autoimmune disorder characterized by
the destruction of insulin‐producing pancreatic β‐cell mediated by
autoreactive immune cells1 that involves both innate and adaptive
immunity.2 Toll-like receptors (TLRs) are a family of pattern
recognition receptors that can induce innate immune responses
and modulate adaptive immunity and are widely expressed on/in a
variety of immune and nonimmune cells.3 Most surface-expressed
TLRs can recognize microbe-derived lipids, lipoproteins, and
proteins; additionally, several intracellular TLRs, including TLR3,
TLR7, TLR8, and TLR9, sense bacterial and viral nucleic acids.4,5 In
addition to roles in immune responses to pathogens, TLRs can
modulate the susceptibility to autoimmune diseases, such as
systemic lupus erythematosus (SLE)6,7 and arthritis.8 In SLE-prone
MRL/lpr mice, TLR7 promotes anti-nuclear autoantibody generation
and disease development, while TLR9 protects against disease.9
TLR9 also regulates TLR7-dependent autoantibody production and
disease progression in MRL/lpr mice,10 suggesting important
crosstalk between these TLRs. In T1D studies, Tlr2 or Tlr9 deficiency
in nonobese diabetic (NOD) mice led to protection from T1D
development,11–14 whereas Tlr4 deficiency accelerated disease
progression.15,16 TLR7, another member of the TLR family, is mainly
expressed in immune cells4,5,17 and can recognize single-stranded
RNA (ssRNA), a common feature of viral genomes.18 However, it is
unclear what role TLR7 plays in the context of T1D.
Our previous study identified that norovirus, a murine enteric
ssRNA virus, activates TLR7 and modulates susceptibility to T1D in
NOD mice.19 In addition, rotavirus, an enteric double-stranded
RNA virus, can also activate TLR7 to promote lymphocyte
activation.20 Interestingly, the activation of immune cells from
NOD mice in response to rotavirus stimulation in vitro was weaker
compared with that of immune cells from C57BL/6 mice.20 In
contrast, in vivo activation of TLR7 in a diabetogenic CD8 T-cell
receptor (TCR) transgenic NY8.3 NOD mouse model accelerated
diabetes development.21 To ascertain the role of TLR7 in
mediating the susceptibility to T1D, we investigated the TLR7-
dependent modulation of the immune system that may alter the
susceptibility to T1D by using Tlr7-deficient (Tlr7−/−) NOD mice.
MATERIALS AND METHODS
Mice
All the mice used in this study were kept in specific pathogen-free
conditions with a 12-h dark/light cycle at the Yale University
animal facility. NOD/Caj mice were originally obtained from the
Jackson Laboratory and have been maintained at Yale University.
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Tlr7−/− C57BL/6 breeders, which were kindly provided by Prof.
Richard Flavell (Yale University),22 were backcrossed to the NOD/
Caj genetic background for 12 generations. The purity of the NOD
genetic background was examined by mouse genome scan using
an Illumina SNP chip (DartMouse). BDC 2.5 CD4+ TCR transgenic
NOD mice, NY8.3 CD8+ TCR transgenic mice and Rag-deficient
(Rag−/−) NOD mice were originally obtained from the Jackson
Laboratory and have been maintained at Yale University. The use
of the animals in this study was approved by the Institutional
Animal Care and Use Committee of Yale University.
Natural history of diabetes development
Tlr7−/− NOD mice and Tlr7+/+ NOD mice (wild-type NOD mice)
were observed for spontaneous diabetes development by screen-
ing for glycosuria weekly for 40 weeks. Diabetes was confirmed by
a blood glucose concentration ≥ 250mg/dl (13.9 mmol/l).
Insulitis score
Mice were dissected, and the pancreata were collected during the
prediabetic stage (10–12 weeks, female). Pancreatic tissues were
fixed in 10% neutral formalin buffer and embedded in paraffin.
The paraffin-embedded pancreata were then sectioned at a
thickness of 5 μm and stained with hematoxylin and eosin (H&E).
Insulitis was scored under a light microscope using the following
grading scale: 0, no infiltration; 1, <25% infiltration of the islets; 2,
25–50% infiltration of the islets; and 3, >50% infiltration of the
islets.
Cell purification
CD4+ T cells and CD8+ T cells were purified from the spleen of 8-
week-old female Tlr7−/− NOD mice and Tlr7+/+ NOD mice by
negative selection with magnetic beads, according to the
manufacturer’s instructions (QIAGEN). CD4+ T cells were purified
by removing CD8+ T cells (clone: T1B105), MHC class II+ cells
(clone: 10.2.16), and B cells (anti-mouse IgM and IgG) using mAb
hybridoma supernatants, followed by magnetic bead separation
(conjugated with goat anti-rat IgG). CD8+ T cells were purified by
removing CD4+ T cells (clone: GK1.5), MHC class II+ cells (clone:
10.2.16), and B cells (anti-mouse IgM and IgG). Splenic B cells were
purified with an EasySepTM Mouse B-cell isolation kit purchased
from STEMCELL Technologies. The purity was routinely 90–95%, as
verified by flow cytometry.
CFSE-labeled cell proliferation in vivo
Purified splenic CD4+ BDC 2.5 T cells were labeled with CFSE and
injected i.v. (3 × 106/mouse) into 8-week-old female Tlr7−/− NOD
mice and Tlr7+/+ NOD mice. Three days later, the recipient mice
were sacrificed, and lymphocytes were collected from the spleen,
pancreatic lymph node (PLN), and mesenteric lymph node (MLN)
for flow cytometric analysis of the proliferative division of CFSE-
labeled cells.
T–B-cell interaction assay
Splenic B cells were purified from 8-week-old female Tlr7−/− NOD
mice and Tlr7+/+ NOD mice. Purified B cells (1 × 105 cells/well)
were treated with mitomycin-C (Sigma) and cocultured with bead-
purified splenic CD4+ T cells from Tlr7−/− NOD mice and Tlr7+/+
NOD mice (T/B= 1:1) in a 96-well plate with different concentra-
tions of an anti-CD3 mAb (2C11 hybridoma supernatant) at 37 °C
in a 5% CO2 incubator for 48 h. The proliferation of CD4
+ T cells
was determined by measuring 3H-thymidine incorporation for 18
h after the 48-h culture with a β-counter.
Transwell cell culture assay
Transwell inserts (Fisher) containing 6.25 × 105 purified B cells in
0.5 ml complete medium were placed in a 24-well plate with an
equal number of bead-purified CD4+ T cells in 0.5 ml medium with
an anti-CD28 antibody (1 µg/ml) and different concentrations of
an anti-CD3 antibody (2C11 hybridoma supernatant). The cells
were incubated at 37 °C in a 5% CO2 incubator for 48 h, and the
proliferation of purified CD4+ T cells in the lower chamber was
assessed by measuring 3H-thymidine incorporation 18 h later.
Adoptive cell transfer experiment
Purified splenic CD4+ T cells (7 × 106) from diabetic wild-type NOD
mice together with purified splenic B cells (7 × 106) from
nondiabetic 8-week-old female Tlr7−/− NOD mice and Tlr7+/+
NOD mice were adoptively transferred (i.v.) into Rag−/− NOD mice
(4–5 weeks old). The recipient mice were monitored for diabetes
development after adoptive transfer by screening for glycosuria
weekly and confirmed to be diabetic by a blood glucose level
greater than 250mg/dl.
Antigen presentation and blocking assay
Purified splenic B cells (1 × 105 cells/well) from 8-week-old female
Tlr7−/− NOD mice or Tlr7+/+ NOD mice were treated with
mitomycin-C prior to coculture with NY8.3 CD8+ T cells (1 × 105
cells/well) in the presence of 200 ng/ml islet-specific glucose-6-
phosphatase catalytic subunit-related protein (IGRP) peptide
(IGRP206-214) for 48 h. For MHC-I blocking, B cells were cultured
in the absence or presence of different concentrations of anti-
classical MHC-I (H2-Kd) and/or anti-nonclassical MHC-I (Qa2) mAbs.
The proliferation of CD8+ T cells was determined with a 3H-
thymidine incorporation assay performed 18 h later with measure-
ment on a β-counter.
Microarray analysis
RNA was extracted from purified splenic B cells from Tlr7−/− NOD
mice and Tlr7+/+ NOD mice (8-week-old females), and cRNA
synthesis and whole-genome microarray analysis were performed
at the Yale Center for Genomic Analysis (Yale University).
GeneChip® WT Plus Reagent Kits (Thermo Fisher Scientific) were
used for sample preparation and ss-cDNA generation. Total RNA
(150 ng) was used for input. Affymetrix GeneChip Mouse Gene 2.0
ST arrays were washed using the GeneChip® Fluidics Station 450
and scanned with the GeneChip Scanner 3000. All the reactions
and hybridizations were carried out according to the manufac-
turer’s protocol.
Cell staining and flow cytometry analysis
Single-cell suspensions (106) from different mouse lymphoid
tissues, including the spleen and lymph nodes, were incubated
with an Fc blocker (clone: 2.4G2) at room temperature for 20 min
before cell-surface staining. For intracellular cytokine (ICC)
staining, cells were incubated at 37 °C for 4 h in the presence of
50 ng/ml PMA (Sigma), 500 ng/ml ionomycin (Sigma) and 1 μl of
Golgi PlugTM (BD Bioscience), followed by incubation with
monoclonal antibodies specific for surface molecules. ICC staining
was then conducted following fixation (20 min, RT) and permea-
bilization using buffers from Tonbo Biosciences. Cells were stained
with antibodies specific for the following surface and intracellular
markers: CD45 (clone: 30-F11), TCRβ (clone: H57-597), CD4 (clone:
GK1.5), CD8 (clone: 53-6.7), CD19 (clone: 6D5), CD21 (clone: 7E9),
CD23 (clone: B3B4), GL-7 (clone: GL-7), IgM (clone: RMM-1), IgD
(clone: RB6-8C5), IgG1 (clone: RMG1-1), IgG2a (clone: RMG2a-62),
IgG2b (clone: RMG2b-1), TNF-α (clone: MP6-XT22), IL-6 (clone:
MP5-20F3), IL-17A (clone: TC11-18H10.1), and IFN-γ (clone:
XMG1.2). The stained cells (1–3 × 105 immune cells) were analyzed
on a BD LSRII flow cytometer, and results were analyzed with
FlowJo 8.8.6 (TreeStar).
Insulin autoantibody and total immunoglobulin detection
Serum samples collected from 8-week-old female Tlr7−/− NOD mice
and Tlr7+/+ NOD mice were tested for anti-insulin autoantibodies by
ELISA. Plates were coated with human insulin (4 μg/ml, Lilly)
overnight. After washing and blocking (1 h, room temperature, 1%
Toll-like receptor 7 deficiency suppresses type 1 diabetes development by. . .
J Huang et al.
2
Cellular & Molecular Immunology _#####################_
BSA in PBS), diluted (1:100) serum samples were tested for total (Ig)
anti-insulin autoantibodies and different isotypes of anti-insulin
autoantibodies with Alkaline phosphatase-conjugated (AP-conju-
gated) goat anti-mouse IgH+L, IgM, IgG, IgA, IgG1, IgG2a, IgG2b,
IgG3 and a phosphate substrate. The enzymatic reaction was
stopped with NaOH, and the plates were read with a microplate
spectrophotometer (Perkin Elmer, Waltham, MA, USA) at OD 405 nm.
Different isotypes of total serum immunoglobulins were also
measured. Briefly, the wells of a 96-well plate were coated with
samples or standards overnight. After washing and blocking (1 h,
room temperature, 1% BSA in PBS), the plates were then incubated
with AP-conjugated goat anti-mouse IgG1, IgG2a, or IgG2b (2 h,
room temperature). The samples were subsequently washed, and
the substrate PNPP (Sigma) was added. The reaction was stopped by
adding 1M NaOH, and the samples were analyzed on a microplate
spectrophotometer at 405 nm (OD).
Cytokine ELISA
Serum and/or supernatant concentrations of TNF-α, IFN-γ, IL-17A,
IL-6, and IL-10 were measured using ELISA kits according to the
manufacturer’s instructions (BioLegend). The TGF-β concentration
in supernatants was measured using an ELISA kit purchased from
R&D Systems.
Antibodies and reagents
The fluorochrome-conjugated monoclonal antibodies used in this
study were purchased from BioLegend or eBioscience. The
supernatants of different monoclonal antibody (mAb) hybridomas
were provided by the late Charles Janeway (Yale University).
Magnetic beads conjugated with goat anti-mouse IgG, goat anti-
mouse IgM, or goat anti-rat IgG were purchased from QIAGEN.
RPMI-1640 medium and heat-inactivated FCS were purchased
from Invitrogen and Gemini, respectively. The anti-H2-Kd mAb
was affinity purified from a hybridoma (clone: HB159) supernatant.
The anti-Qa2 mAb was purchased from BioLegend (clone: 659H1-9-
9). AP-conjugated goat anti-mouse IgH+L, IgG, IgA, IgM, IgG1,
IgG2a, and IgG2b for ELISA were purchased from Southern
Biotechnology.
Data analysis
Statistical analysis was performed using GraphPad Prism software
version 8.0 (GraphPad Software, San Diego, CA, US). Diabetes
incidence was compared using the log-rank test for survival.
Insulitis scores were analyzed using a Chi-square test. In vitro
assays were analyzed with a two-tailed Student’s t test (if the data
were normally distributed), a two-tailed Mann–Whitney test (if the
data were not normally distributed), multiple t tests with the
Bonferroni correction, or two-way ANOVA. The P value and
statistical analysis for each experiment are reported in the figure
legends. P < 0.05 was considered significant.
RESULTS
Tlr7 deficiency suppresses T1D development in NOD mice
To define the role of TLR7 in T1D development, we generated
Tlr7−/− NOD mice by backcrossing Tlr7−/− C57BL/6 mice with NOD
mice for 12 generations. The purity of the NOD genetic
background of Tlr7−/− NOD mouse was confirmed by a mouse
genome scan using an Illumina SNP chip. We first monitored the
natural history of T1D development in Tlr7−/− NOD mice and
Tlr7+/+ NOD littermates. The development of T1D was delayed in
female Tlr7−/− NOD mice, and the overall disease incidence in
these mice was also significantly reduced (Fig. 1A). No significant
difference in the incidence of diabetes development was
observed between male Tlr7−/− NOD mice and male Tlr7+/+
NOD littermates, although the overall incidence of T1D was much
lower in male Tlr7−/− NOD mice than in male Tlr7+/+ NOD
littermates (Fig. 1B). To investigate the effect of Tlr7 ablation on
immune cell infiltration in the pancreatic islets, we randomly
selected prediabetic female Tlr7−/− NOD mice and Tlr7+/+ NOD
littermates (n= 4–7 per group, 10–12 weeks old) and harvested
the pancreas to examine insulitis. In accordance with the
reduction in diabetes development, female Tlr7−/− NOD mice
displayed significantly less insulitis than their female Tlr7+/+ NOD
counterparts (Fig. 1C). Thus, our data showed that Tlr7 deficiency
limited the infiltration of immune cells into the islets, attenuating
the development of T1D in NOD mice.
Tlr7 deficiency alters systemic immune responses in NOD mice
To identify the impact of Tlr7 deficiency on the immune system in
NOD mice, we investigated the phenotypes of immune cells in
both central lymphoid tissues and peripheral lymphoid tissues. We
found that Tlr7 deficiency did not affect thymocyte development,
except for a proportional reduction in the CD4−CD8− compart-
ment in Tlr7−/− NOD mice (Fig. 2A). However, in the absence of
Tlr7, NOD mice had a significant reduction in the frequency of
bone marrow (BM) B cells (Fig. 2B–C). We also found a reduced
proportion of pre–pro B cells in the BM of Tlr7-deficient NOD mice
(Fig. 2D, E). In line with the reduction in the total B-cell frequency
in the BM, the proportions of CD19+ B cells in the spleen, MLN,
and Peyer’s patches (PP) were also significantly lower in Tlr7-
deficient NOD mice than in Tlr7-sufficient NOD mice, whereas no
significant difference was seen in the PLN (Fig. 2F). In addition, the
absence of Tlr7affected peripheral CD4+ T cells but did not
obviously impact CD8+ T-cell development in PP (Fig. 2G, H). Next,
we assessed if Tlr7 deficiency affects macrophages and dendritic
Fig. 1 Blockade of Tlr7 delayed the onset and reduced the development of type1 diabetes. A Natural history of type 1 diabetes development in
female Tlr7+/+ NOD mice (n= 20) and Tlr7−/− NOD littermates (n= 34). Diabetes development was monitored by weekly glycosuria testing and
confirmed by a blood glucose level over 250mg/dl. B Natural history of diabetes development in male Tlr7+/+ NOD mice (n= 14) and Tlr7−/−
NOD littermates (n= 19). C Insulitis scores of female Tlr7+/+ NOD mice and Tlr7−/− NOD mice. Pancreata from nondiabetic female Tlr7+/+ NOD
mice and Tlr7−/− NOD littermates (n= 4–7/group, 10–12 weeks) were fixed in 10% neutral formalin, and insulitis was evaluated under a light
microscope after H&E staining. Insulitis was scored in 164–199 islets per group, and the insulitis scores are shown. Data were pooled from at
least two independent experiments and analyzed using the log-rank test for survival (A, B) and a Chi-square test (C)
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cells (DCs). There were changes in macrophage populations, but
we did not find any alterations in the frequencies of conventional
DCs (cDCs) and plasmacytoid dendritic cells (pDCs) (Fig. S1A–C).
We also measured the type 1 IFN (IFN-α) concentration in the
serum. Interestingly, Tlr7 knockout mice had levels of circulating
IFN-α similar to those of their wild-type counterparts (Fig. S1D).
Taken together, our results show that Tlr7 deficiency alters the
development of immune cells, particularly B cells, in NOD mice.
Tlr7 deficiency alters B-cell differentiation and immune responses
Next, we determined whether peripheral B-cell subsets are
affected by Tlr7 deficiency and found that the proportion of
CD21hiCD23low B cells was significantly increased in all the
peripheral lymphoid tissues of Tlr7−/− NOD mice examined
(Fig. 3A), whereas the proportion of CD21lowCD23hi B cells was
reduced, although mostly in the spleen (Fig. 3B). The proportion of
germinal center B cells (PNA+GL-7+) was also significantly reduced
in Tlr7-deficient NOD mice (MLN and PP) compared with Tlr7-
sufficient NOD mice (Fig. 3C). Interestingly, the proportions of
CD1d+CD5+ B cells (the common phenotype for Bregs) in the
spleen and MLN were significantly increased in Tlr7-deficient NOD
mice (Fig. 3D). The increased Breg populations were also observed
in the PLN and PP, although these increases were not statistically
significant (Fig. 3D). In addition, we found that B cells in Tlr7−/−
NOD mice expressed lower levels of CD40 and CXCR5 than those
in Tlr7+/+ NOD mice (Fig. 3E, F). The expression of IL-6, which is
essential for B-cell differentiation, maturation and survival,23 was
reduced in splenic B cells from Tlr7−/− NOD mice (Fig. 3G). The
circulating IL-6 concentration was also reduced in Tlr7−/− NOD
mice (Fig. 3H). Furthermore, we found that splenocytes from
Tlr7−/− NOD mice displayed attenuated responses to adaptive
immune stimulation with an anti-CD40 antibody (Fig. 3I), and
importantly, purified splenic B cells showed attenuated responses
to stimulation with an anti-IgM antibody in the presence of the
Fig. 2 Tlr7 deficiency altered systemic immune responses in NOD mice. A The percentages of thymic CD4−CD8−, CD4+CD8+, CD4+, and CD8+
cells, gated from live single cells from 8-week-old female Tlr7+/+ and Tlr7−/− NOD mice. B, C The proportion of CD19+ B cells in the bone
marrow of 8-week-old female Tlr7+/+ and Tlr7−/− NOD mice, gated from live single cells. Representative flow cytometric plots (B) and the
summarized percentage of CD19+ B lymphocytes (C) are shown. D, E The percentages of pre–pro B cells, immature B cells, transitional B cells,
early mature B cells and late mature B cells in the bone marrow of 8-week-old female Tlr7+/+ and Tlr7−/− NOD mice. Representative flow
cytometric plots with further gating of CD19+ B cells (D) and the summarized percentages of each B lymphocyte subset (E) are shown. F The
proportions of CD19+ B cells in the spleen, PLN, MLN, and PP of 8-week-old female Tlr7+/+ and Tlr7−/− NOD mice, as analyzed by flow
cytometry. Cells were gated from the initial population of live single TCR-β− cells. G, H The percentages of CD4+ T cells and CD8+ T cells in 8-
week-old female Tlr7+/+ and Tlr7−/− NOD mice. Representative flow cytometric plots were gated from the initial population of CD19−TCR−β+
T cells (G), and the summarized percentages of CD4+ and CD8+ T lymphocytes (H) are shown. Data pooled from two independent
experiments (A, C, E, F, H) were analyzed by a two-tailed Student’s t-test or a two-tailed Mann–Whitney test and are represented as the mean ±
SD (n= 6–7/group). FSC forward scatter, PLN pancreatic lymph node, MLN mesenteric lymph node, PP Peyer’s patches
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anti-CD40 antibody (Fig. 3J). Our results demonstrate that Tlr7
deficiency in NOD mice not only affects the differentiation of B
cells but also decreases the functional responses of these cells.
Tlr7 deficiency alters B-cell immunoglobulin production
Autoantibodies against islet autoantigen(s) have been used as
biomarkers for the prediction and diagnosis of T1D, especially in
humans.24 As Tlr7 deficiency has strong impacts on B-cell
development and functional responses, we hypothesized that
the ability of Tlr7-deficient B cells to produce (auto)antibodies may
also be altered. To test our hypothesis, we measured the levels of
anti-insulin antibodies in the serum of prediabetic (8-week-old)
Tlr7+/+ NOD mice and Tlr7−/− NOD mice. Interestingly, we found
that the anti-insulin autoantibody levels in the Tlr7−/− NOD mice
were indeed much lower than those in the Tlr7+/+ NOD mice,
except for the IgM isotype level, which was increased (Fig. 4A).
Furthermore, we found that the level of anti-insulin IgG antibodies
showed the greatest reduction (Fig. 4A), suggesting that Tlr7 is
important for class switching. We further assessed the levels of
different IgG subclasses of anti-insulin antibodies and found that
the lower levels of IgG2a and IgG2b likely contributed to the
overall decreased level of anti-insulin IgG antibodies (Fig. 4B).
Interestingly, the level of anti-insulin IgG1 antibodies was higher in
Tlr7-deficient mice than in Tlr7-sufficient mice (Fig. 4B). Moreover,
we found that the total serum antibody concentrations of the
IgG subclasses (Fig. 4C) and frequencies of different IgG
Fig. 3 Tlr7 deficiency affects the differentiation and functional responses of B cells. A–D The percentages of B-cell subsets in 8-week-old
female Tlr7−/− and Tlr7+/+ NOD mice. CD21hiCD23low (A, n= 6–7/group), CD21lowCD23hi (B, n= 6–7/group), PNA+GL-7+ (C, n= 6–7/group),
and CD1d+CD5+ (D, n= 11–12/group), gated from the initial population of TCRβ−CD19+ B cells. E, F The proportions of splenic B cells
expressing specific activation markers in 8-week-old female Tlr7−/− and Tlr7+/+ NOD mice. CD40+ (E, n= 6–7/group) and CXCR5+ (F, n= 6/
group) B cells, gated from the initial population of TCR-β−CD19+ B cells. G The proportion of IL-6-secreting splenic B cells in female Tlr7−/− and
Tlr7+/+ NOD mice (n= 6–7/group). Cells were gated from the initial population of TCRβ−CD19+ B cells. H Serum IL-6 concentration in 8-week-
old female Tlr7−/− and Tlr7+/+ NOD mice (n= 19/group). I, J Proliferation of splenocytes (I) or purified splenic B cells (J) (5 × 104 cells/well) from
8-week-old female Tlr7−/− and Tlr7+/+ NOD mice. The proliferation of splenocytes cultured with different concentrations of an anti-CD40
antibody (I) and purified splenic B cells cultured with different concentrations of an anti-IgM antibody in the presence of the anti-CD40
antibody (J) was evaluated. Data pooled from at least two independent experiments (A–H) are shown as the mean ± SD and were analyzed by
a two-tailed Student’s t-test or a two-tailed Mann–Whitney test. The data shown in (I–J) are from one of three representative experiments, all
of which showed consistent results and were analyzed using two-way ANOVA. PLN pancreatic lymph node, MLN mesenteric lymph node, PP
Peyer’s patches. ΔCPM represents counts per minute after subtracting the background
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subclass-poroducing B cells were in accordance with the serum
levels of anti-insulin antibodies, particularly for IgG2b (Fig. 4D–F).
Tlr7-deficient B cells attenuate CD4+ T-cell functions in a cell
contact-dependent manner
As CD4+ T cells are known to play important roles in the destruction
of pancreatic β cells and T1D development, we next investigated
whether Tlr7 deficiency affects CD4+ T-cell activation and function.
Surprisingly, we observed increased IFN-γ-producing CD4+ T-cell
frequencies in most peripheral lymphoid tissues in Tlr7-deficient
NOD mice (Fig. S2A). We also observed more IL-17A-producing and
TNF-α-producing CD4+ T cells in the PP of Tlr7-deficient NOD mice
than in those of wild-type mice (Fig. S2B, C). When testing for ICC
production (i.e., the potential of cells to produce a cytokine), cells
were commonly stimulated with PMA and ionomycin, which bypass
TCR engagement. To investigate whether TCR engagement actually
leads to increased inflammatory cytokine-producing CD4+ T-cell
frequencies in Tlr7-deficient NOD mice, we stimulated total
lymphocytes with an anti-CD3 antibody, which directly engages
the TCR, in the presence of Golgi PlugTM, (omitting the standard
treatment with PMA and ionomycin that bypasses TCR signaling) for
4 h. Our results showed that direct TCR engagement through anti-
CD3 stimulation did not lead to increased IFN-γ/IL-17A/TNF-α-
producing CD4+ T-cell frequencies in Tlr7−/− NOD mice (Fig. 5A–C).
These results suggest that Tlr7 deficiency does not have direct
effects on cytokine-producing CD4+ T cells, as T-cell activation
in vivo is mediated by TCR engagement via antigen recognition. To
further determine whether Tlr7-deficient B cells influence diabeto-
genic CD4+ T-cell actions in vivo, we labeled purified BDC 2.5 CD4+
T cells (Tlr7 sufficient) with CFSE and intravenously transferred the
cells into Tlr7−/− NOD mice or Tlr7+/+ NOD mice. Three days later,
we harvested immune cells from different lymphoid tissues of the
recipients and evaluated the proliferation of BDC 2.5 CD4+ T cells by
flow cytometry. It was found that BDC 2.5 CD4+ T cells proliferated
poorly, particularly in the PLN, in the Tlr7-deficient hosts compared
with the Tlr7-sufficient hosts (Fig. 5D). This suggests that in situ Tlr7-
deficient antigen-presenting cells (APCs) contribute to the suppres-
sion of diabetogenic T-cell expansion in the absence of Tlr7.
To test if B cells are responsible for this suppression, we
stimulated both Tlr7-sufficient CD4+ T cells and Tlr7-deficient
CD4+ T cells with an anti-CD3 antibody in the presence of B cells
from either Tlr7+/+ NOD mice or Tlr7−/− NOD mice. Interestingly,
the CD4+ T-cell proliferative response was significantly impaired
(Fig. 5E) in the presence of Tlr7-deficient B cells, implying that the
cross-linking function of Tlr7-deficient B cells was less efficient
than that of Tlr7-sufficient B cells in this context of anti-CD3
antibody stimulation. To further test if Tlr7-deficient B cells
attenuate diabetes development, we adoptively transferred Tlr7-
deficient or Tlr7-sufficient B cells together with purified CD4+
T cells (Tlr7 sufficient) from diabetic NOD mice into immunodefi-
cient Rag−/− NOD recipients. In line with the in vitro coculture
results, the Tlr7-deficient B cells significantly delayed the diabetes
development induced by diabetogenic CD4+ T cells in the Rag−/−
NOD recipients (Fig. 5F).
To investigate whether the suppressive function of Tlr7-deficient B
cells is mediated by soluble cytokine release, we examined the IL-10
and TGF-β concentrations in the supernatant of the cocultures
described above (Fig. 5E). Unexpectedly, there were no significant
differences in the IL-10 or TGF-β concentration in the culture
supernatants (Fig. 5G, H). Therefore, to determine whether B cells
modulate CD4+ T cells directly through cell–cell contact, we used a
transwell culture system, in which Tlr7-deficient B cells were
cocultured indirectly with CD4+ T cells. Interestingly, when purified
B cells from Tlr7−/− NOD mice had no contact with Tlr7−/− NOD
CD4+ T cells, we found an increase in CD4+ T-cell proliferation
(Fig. 5I), which was distinctly different from the suppression seen
when CD4+ T cells were in direct contact with Tlr7−/− NOD B cells
(Fig. 5E).
Fig. 4 Tlr7 deficiency affects the production of immunoglobulin by B cells. A Serum anti-insulin total Ig, IgM, IgG, and IgA autoantibody levels
in 8-week-old female Tlr7−/− and Tlr7+/+ NOD mice. Data are presented as the optical density (OD) measured at 405 nm (n= 12–16/group).
B Serum anti-insulin IgG1, IgG2a, IgG2b, and IgG3 autoantibody levels in female Tlr7−/− and Tlr7+/+ NOD mice (n= 12–16/group). C Total
serum IgG1, IgG2a, and IgG2b antibody concentrations in 8-week-old female Tlr7−/− and Tlr7+/+ NOD mice (n= 12–16/group).
D–F Proportions of IgG1+ (D), IgG2a+ (E) and IgG2b+ (F) B cells in the spleen, PLN, MLN, and PP of 8-week-old female Tlr7−/− and Tlr7+/+
NOD mice (n= 6–7/group). Cells were gated from the initial population of TCRβ−CD19+ B cells. Data pooled from two independent
experiments (A–F) were analyzed by a two-tailed Student’s t-test or a two-tailed Mann–Whitney test and are shown as the mean ± SD. PLN
pancreatic lymph node, MLN mesenteric lymph node, PP Peyer’s patches
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To assess how TLR7 affects the crosstalk between B cells and
CD4+ T cells, we investigated the expression patterns of
costimulatory molecules and chemokine receptors on both B
cells and CD4+ T cells. We found that the levels of PD-L1 and CD80
were significantly increased on splenic B cells in Tlr7−/− NOD mice
compared with splenic B cells in Tlr7+/+ NOD mice (Fig. 5J, K); in
contrast, no difference was found in PD-1 on CD4+ T cells. To
investigate if PD-L1 contributes to the attenuated CD4+ T-cell
response observed when Tlr7-deficient B cells are in direct contact
with CD4+ T cells, we then blocked PD-L1 with a monoclonal
antibody in an antigen-specific T-cell assay. To this end, we
cocultured islet autoantigen-specific BDC 2.5 CD4+ T cells with
mitomycin-C-treated B cells from Tlr7−/− NOD mice or Tlr7+/+
NOD mice, which were used as APCs, in the presence of an
antigenic peptide with and without an anti-PD-L1 antibody.
Interestingly, we showed that the Tlr7−/− NOD B cells but not the
Tlr7+/+ NOD B cells were responsive to blockade with the PD-L1-
specific immune checkpoint inhibitor, and hence, the proliferation
of BDC 2.5 CD4+ T cells was increased (Fig. 5L). Taken together,
our data suggest that Tlr7−/− B cells in NOD mice restrain CD4+ T-
cell responses by cell–cell contact, which is potentially mediated
through PD-L1.
Tlr7 deficiency modulates antigen presentation by B cells to CD8+
T cells by regulating nonclassical and classical MHC-I molecule
expression
In addition to CD4+ T cells, cytotoxic CD8+ T cells play essential
roles in β-cell damage and T1D development.25–29 Thus, we also
investigated the role of Tlr7 deficiency in regulating CD8+ T cells in
Tlr7−/− NOD mice. Similar to the results for CD4+ T cells (Fig. S2A),
Fig. 5 The effect of Tlr7 deficiency on CD4+ T cells in NOD mice. A–C Expression levels of IFN-γ, IL-17A, and TNF-α in CD4+ T cells after anti-
CD3 stimulation (n=8/group). IFN-γ (A), IL-17A (B), and TNF-α (C). D BDC 2.5 CD4+ T-cell proliferation in vivo. CFSE-labeled BDC 2.5 CD4+
T cells were injected into 8-week-old female Tlr7−/− or Tlr7+/+ NOD mice, and cell proliferation was evaluated by flow cytometry.
E Proliferation of Tlr7−/− or Tlr7+/+ NOD CD4+ T cells cocultured with purified Tlr7−/− NOD B cells in the presence of an anti-CD3 antibody.
F Purified splenic B cells from Tlr7−/− or Tlr7+/+ NOD mice were cotransferred with purified CD4+ T cells from diabetic NOD mice into Rag−/−
NOD recipient mice, followed by observation for diabetes development. G–H IL-10 (G) and TGF-β (H) concentrations in the supernatant of
Tlr7−/− or Tlr7+/+ NOD CD4+ T cells cocultures with purified splenic Tlr7−/− NOD B cells in the presence of an anti-CD3 antibody (n= 6/group).
I Proliferation of Tlr7−/− or Tlr7+/+ NOD CD4+ T cells cocultured with purified splenic Tlr7−/− NOD B cells in a Transwell system. J–K Expression
of PD-L1 (J) and CD80 (K) on splenic CD19+ B cells. L Proliferation of BDC 2.5+ NOD CD4+ T cells cocultured with purified Tlr7−/− or Tlr7+/+
NOD B cells in the presence of different concentrations of an anti-PD-L1 antibody. The data in (A–C, F–H, J, K) were pooled from two or more
independent experiments. The experiments in (D, E, I, L) were performed twice, and consistent results were obtained. Data were analyzed
using a two-tailed Student’s t-test (A–D, G, H, J, K), two-way ANOVA (E, I, L), or the log-rank test for survival (F). The data in (A–D, G, H, J, K) are
shown as the mean ± SD. PLN pancreatic lymph node, MLN mesenteric lymph node, PP Peyer’s patches. ΔCPM represents counts per minute
after subtracting the background
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increased IFN-γ expression was observed in CD8+ T cells from the
PLN and PP in Tlr7−/− NOD mice after stimulation with PMA/
ionomycin ex vivo (Fig. S3), but no difference was found if the cells
were stimulated with an anti-CD3 antibody (Fig. 6A). However,
when we assessed the antigen presentation by B cells to
diabetogenic NY8.3 CD8+ T cells, our results showed that the
antigen-presenting ability of Tlr7−/− NOD B cells was significantly
impaired, as indicated by reduced NY8.3 CD8+ T-cell proliferation
(Fig. 6B). Interestingly, our microarray analysis of purified splenic B
cells from Tlr7−/− NOD mice and Tlr7+/+ NOD mice showed that
Tlr7 deficiency significantly decreased the expression of non-
classical MHC-I (MHC-Ib)-encoding genes including H2-Q6/8 and
H2-Q7/9 in B cells (Fig. 6C), which are Qa2 antigen-encoding
genes.30 We further confirmed the significantly decreased
expression of H2-Q6/8 and H2-Q7/9 in Tlr7−/− NOD B cells by
real-time qPCR (Table 1 and Fig. 6D, E). Although classical MHC-I
and MHC-II gene expression was not significantly different
between Tlr7+/+ NOD B cells and Tlr7−/− NOD B cells (Fig. 6C),
the protein expression of the classical MHC-I molecule H2-Kd on
splenic B cells was significantly reduced in Tlr7−/− NOD mice
compared with Tlr7+/+ NOD mice (Fig. 6F, G). To investigate the
roles of the nonclassical MHC-I molecule Qa2 and the classical
MHC-I molecule H2-Kd in CD8+ T-cell proliferation, we performed a
blocking assay in which mitomycin-C-treated wild-type NOD B
Fig. 6 The effect of Tlr7 deficiency on CD8+ T cells in NOD mice. A Expression levels of IFN-γ in CD8+ T cells after anti-CD3 stimulation (n= 8/
group). B NY8.3 CD8+ T-cell proliferation in vitro. NY8.3 CD8+ T cells were cultured with purified B cells from either Tlr7+/+ NOD mice or Tlr7−/−
NOD mice, in the presence of different concentrations of the IGRP peptide. CMicroarray results. The heat map shows gene expression levels in
purified splenic B cells from 8-week-old female Tlr7+/+ or Tlr7−/− NOD mice (n= 2/group). Normalized gene expression values are plotted
based on the data ranges, where lower gene expression is represented in green, while higher gene expression is represented in red. ***P <
0.001 for both H2-Q6/8 comparisons and H2-Q7/9 comparisons. D–E qPCR results for the gene expression of H2-Q6/8 (D) and H2-Q7/9 (E) in
purified splenic B cells from 8-week-old female Tlr7+/+ and Tlr7−/− NOD mice (n= 6/group). F–G Flow histogram (F) and summarized
percentage of H2-Kd expression (G) on splenic CD19+ B cells from 8-week-old female Tlr7+/+ or Tlr7−/− NOD mice (n= 6/group). The data in
(A, D, E, G) were pooled from two independent experiments. The experiments in (B) were performed twice, and consistent results were
obtained. The data were analyzed using a two-tailed Mann–Whitney test (A, E), two-way ANOVA (B), multiple t-tests with the Bonferroni
correction (C), or a two-tailed Student’s t-test (D, G). PLN pancreatic lymph node, MLN mesenteric lymph node, PP Peyer’s patches, IGRP islet-
specific glucose-6-phosphatase catalytic subunit-related protein. ΔCPM represents counts per minute after subtracting the background
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cells were used as APCs and cocultured with NY8.3 CD8+ T cells in
the presence of an anti-H2-Kd mAb and/or anti-Qa2 mAb. As
expected, the anti-H2-Kd mAb markedly inhibited the proliferation
of NY8.3 CD8+ T cells; interestingly, the anti-Qa2 mAb further
suppressed the activation of CD8+ T cells (Fig. 7A). However, the
anti-Qa2 mAb alone did not have a suppressive effect on CD8+ T-
cell activation (Fig. 7A). When we assessed the blocking ability in
culture, the suppressive effect was much greater for both the anti-
H2-Kd mAb alone and the anti-H2-Kd mAb together with the anti-
Qa2 mAb when Tlr7−/− NOD B cells were used as APCs than when
Tlr7+/+ NOD B cells were used as APCs (Fig. 7B, C). In addition to
suppressing CD8+ T-cell proliferation, blocking Qa2 and H2-Kd on
B cells simultaneously inhibited CD8+ T-cell secretion of proin-
flammatory TNF-α (Fig. 7D) but not that of IFN-γ and IL-17A (data
not shown). Taken together, our studies suggest that Tlr7
deficiency in NOD mice leads to impaired antigen presentation
by B cells to antigen-specific CD8+ T cells by reducing the
expression of nonclassical and classical MHC-I molecules on B
cells.
DISCUSSION
Our studies provide novel insights into the role of TLR7 in the
context of T1D. We demonstrated that Tlr7 deficiency suppresses
the development of diabetes by altering predominantly B-cell
development, differentiation, and functions. Specifically, we found
that in the absence of Tlr7, B cells expressed increased levels of
PD-L1, suppressing CD4+ T cells, and the expression levels of both
nonclassical MHC-I molecules and classical MHC-I molecules were
reduced, limiting the proliferation of antigen-specific CD8+ T cells.
To our knowledge, this is the first time that nonclassical MHC-I has
been shown to be regulated by TLR7; therefore, we have identified
a novel mechanism to limit the activation of T cells in autoimmune
diabetes and likely in multiple disease settings.
It is known that TLR7, the receptor for ssRNAs including self
RNA, plays an important role in modulating the immunopatho-
genesis of systemic autoimmune disorders, such as SLE.6,31
Autoantibodies to nuclear antigens play an essential role in the
immunopathogenesis of SLE, a spectrum of systemic autoimmune
disorders. In Tlr7-deficient mouse models of SLE, disease is
ameliorated due to diminished anti-RNA autoantibody levels and
suppressed nephritis development.9 However, Tlr7 deficiency does
not affect anti-dsDNA autoantibody development, which is TLR9
dependent.9 Moreover, studies in both humans with SLE and
mouse models of SLE have shown that IFNα also contributes to
the immunopathogenesis of this disease.32–34 Unlike SLE, T1D is
an organ-specific autoimmune disorder mediated mostly by
autoreactive T cells. However, the role of TLR7 in T1D was
previously unclear. TLR7 has been detected on APCs in the
pancreas of patients with newly diagnosed T1D,35 suggesting that
TLR7 may play a role in the immunopathogenesis of T1D
development. Using Tlr7-deficient NOD mice, we found that
TLR7 contributes to T1D development, as diabetes development
was found to be suppressed in NOD mice lacking Tlr7. This disease
suppression is mediated by alterations in B-cell differentiation and
functions. In the absence of Tlr7, there were reductions in the
number of total B cells in both the BM and peripheral lymphoid
tissues. Interestingly, the frequencies of the subsets of marginal
zone B cells (CD21hiCD23low) and Breg cells (CD1d+CD5+) were
significantly increased in the periphery, whereas those of follicular
B cells (CD21lowCD23hi) and germinal center B cells (PNA+GL-7+)
were markedly reduced. Importantly, in the absence of Tlr7, B cells
were hyporeactive to immune stimuli and their antigen presenta-
tion to T cells was impaired in vitro. Moreover, Tlr7-deficient B cells
Fig. 7 The effect of Tlr7-deficient B cells on cytotoxic CD8+ T-cell activation in NOD mice. A Proliferation of NY8.3 CD8+ T cells cocultured with
purified splenic wild-type NOD B cells in the presence of 100 ng/ml IGRP and different concentrations of an anti-H2-Kd mAb and/or anti-Qa2
mAb. B, C Proliferation of NY8.3 CD8+ T cells cocultured with purified splenic Tlr7+/+ or Tlr7−/− NOD B cells in the presence of 100 ng/ml IGRP
and different concentrations of the anti-H2-Kd mAb (B) or the anti-H2-Kd mAb together with the anti-Qa2 mAb (C). D TNF-α concentration in
the supernatant of NY8.3 CD8+ T cells cocultured with purified splenic NOD B cells in the presence of 100 ng/ml IGRP and different
concentrations of the anti-H2-Kd mAb and/or anti-Qa2 mAb (n= 6/group). The experiments in (A–C) were performed twice, and consistent
results were obtained. The data in (D) were pooled from two independent experiments. Data were analyzed using two-way ANOVA (A–D)
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modulated diabetogenic T cells in vivo. Despite the immunoto-
lerant and regulatory features of Tlr7-deficient B cells, surprisingly,
these B cells did not produce the immunoregulatory cytokines IL-
10 and TGF-β.
Having identified that both autoantibody secretion and
antibody-secreting cell frequencies were reduced in Tlr7-deficient
NOD mice, we investigated the modulatory impact of TLR7 on B-
cell interactions with CD4+ T cells. Tlr7−/− B cells suppressed CD4+
T cells in a contact-dependent manner, as evidenced by increased
proliferation of Tlr7−/− CD4+ T cells observed when these cells
were cultured in a transwell system that separated the CD4 T cells
from direct B-cell contact. This contact-dependent suppression
was due to upregulation of PD-L1 expression on Tlr7−/− B cells,
which directly suppressed diabetogenic CD4+ T-cell proliferation,
as indicated by the reversal of suppression achieved by blocking
PD-L1. This suppression was orchestrated predominantly by
changes to PD-L1 on B cells, as PD-1 on CD4+ T cells was not
altered. Our data support the notion of “checkpoint” inhibition by
PD-1/PD-L1 interactions that can limit T-cell proliferation and
reduce antibody titers.36
To further probe the molecular differences in B cells in the
absence of Tlr7, we investigated MHC gene expression and
demonstrated significant differences in H2-Q6/8 and H2-Q7/9,
which are nonclassical MHC class Ib genes, and the expression
of these genes was markedly downregulated in Tlr7-deficient B
cells. We also found that the protein expression of classical
MHC-I molecules was reduced on Tlr7-deficient B cells. MHC-I
plays a critical role in T1D development, and the expression of
both classical MHC-I and nonclassical MHC-I molecules is
enhanced in the islets of patients with T1D37; conversely,
MHC-I deficiency is sufficient to prevent β-cell destruction by
autoreactive CD8+ T cells and T1D development in NOD mice.38
Interestingly, we found that Tlr7−/− NOD B cells could inhibit
the proliferation of cytotoxic CD8+ T cells. Thus, our studies
provide new insights into the regulation of MHC-I-restricted
cytotoxic CD8+ T cells in the pathogenesis of T1D by TLR7. It is
noteworthy that our study also identified a link between TLR7
and IL-6, as IL-6 expression was significantly reduced in the
absence of Tlr7.
Although CD4+ and CD8+ T cells have been demonstrated to play
essential roles in the damage to pancreatic β cells occurring during
the development of the T1D,2,27,39–41 B cells are critical in facilitating
T-cell-mediated autoimmunity.42 Studies on animal models of
human T1D show that B-cell-deficient mice are protected from
T1D development, suggesting that B cells are also important in the
immunopathogenesis of T1D.42–45 Moreover, we previously found
that individuals newly diagnosed with T1D had an increased
frequency of marginal zone B cells (MZB) but a decreased frequency
of follicular B cells (FoB), which are closely associated with altered β-
cell function, indicating that B cells are involved in the process of
loss of self-tolerance to β cells.46 In the current study, we found that
Tlr7−/− NOD B cells effectively suppressed pathogenic CD4+ T-cell
responses and inhibited the development of diabetes in a second
host. Moreover, we discovered that Tlr7−/− NOD B cells could
significantly suppress the activation and proliferation of cytotoxic
CD8+ T cells by regulating the expression of both nonclassical MHC-I
molecules and classical MHC-I molecules on B cells. Taken together,
our studies show that TLR7 expression on B cells alters their
interactions with T cells and thus contributes to the development of
T1D. Therefore, targeting TLR7 and/or modulating its function could
become an important therapy for T1D.
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